文摘

Purpose The authors prospectively compared single dose (0.1?mmol/kg bodyweight) gadobenate dimeglumine with double dose (0.2?mmol/kg bodyweight) gadopentetate dimeglumine for contrast-enhanced magnetic resonance angiography (CE-MRA) in patients with suspected or known steno-occlusive disease of the carotid, renal or peripheral vasculature using an intra-individual crossover study design. Materials and methods Twenty-eight patients with suspected or known steno-occlusive disease of the carotid (n?=?16), renal (n?=?5) or peripheral arteries (n?=?7) were randomised to receive either 0.1?mmol/kg gadobenate dimeglumine or 0.2?mmol/kg gadopentetate dimeglumine for a first CE-MRA procedure. After 3-?days all patients underwent a second identical CE-MRA procedure with the other contrast agent. Three blinded readers assessed images for vessel anatomical delineation, disease detection/exclusion, and global preference. Diagnostic performance for detection of ?1?% stenosis was determined for 20/28 patients who also underwent digital subtraction angiography (DSA). Non-inferiority was assessed using the Wilcoxon signed rank, McNemar and Wald tests. Quantitative (signal-to-noise and contrast-to-noise ratio) enhancement based on 3D maximum intensity projection reconstructions was compared. Results No differences were noted for any qualitative parameter. Equivalence was reported for all diagnostic preference end-points. Superiority for gadobenate dimeglumine was reported by all readers for sensitivity for disease detection (80.8-6.5 vs. 75.0-2.7?%). Quantitative enhancement was similar for single dose gadobenate dimeglumine and double dose gadopentetate dimeglumine. Conclusions Under identical examination conditions a single 0.1?mmol/kg body weight dose of gadobenate dimeglumine can fully replace a double 0.2?mmol/kg body weight dose of gadopentetate dimeglumine for routine CE-MRA procedures.